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therapeutic targets. Drugs already marketed that open K1Potassium channel openers as potential therapeutic weapons in
channels were discovered empirically, and most have seriousion channel disease. The opening of potassium (K1) channels,
safety and efficacy problems. New scientific methods, utilizingcausing hyperpolarization of the cell membrane, is a physiologi-
molecular insight, are implicating K1 channel dysfunction incal means of decreasing cell excitability. Thus, drugs with this
numerous disease states and are identifying new targets forproperty will demonstrate a broad clinical potential. The identi-
the future generation of K1 channel opening drugs.fication of synthetic molecules that evoke physiological re-
sponses (for example smooth muscle relaxation) by the opening
of K1 channels led to a new direction in the pharmacology
of ion channels. The term “potassium channel openers” was
The transmembrane movement of Na1, K1, Ca21 andinitially associated with a group of chemically diverse agents
Cl2 ions is a principal pathway by which stimuli to the(for example, cromakalim, pinacidil, nicorandil) that evoke K1
efflux through adenosine 59-triphosphate (ATP)-sensitive K1 extracellular membrane are transduced to the cytoplasm.
channels (KATP). This finding initiated a search to identify mole- Modified efflux and influx of these ions through specific
cules that specifically open other K1 channel subtypes (for plasmalemma channels will evoke changes in the mem-example large conductance calcium-activated K1 channels
brane potential that are associated with the initiation,[BKCa]). K1 channel opening properties have been demon-
modulation or termination of cellular activities. The ef-strated in a diverse range of synthetic chemical structures and
endogenous substances. Second generation KATP channel open- flux of K1 ions following opening of K1 channels is a
ers (KATPCOs) demonstrate heterogeneous pharmacology in- mechanism that cells use to maintain or restore a resting
dicative of independent sites of action for the different agents. state or attenuate the level of depolarizing effects pro-Successful cloning of the KATP channel has shed light on the
duced by excitatory currents. This occurs because of aheterogeneity of the structure targeted by KATPCOs. Expression
shift of the membrane potential towards the equilibriumof the actions of KATPCOs involves three isoforms of the sulfo-
nylurea (SUR) receptor (which forms the b subunit of the KATP potential of potassium (EK, that is, the membrane poten-
channel). The distribution of the SUR isoforms (and potential tial that would be produced if the K1 ions were in equilib-
of identifying new isoforms) provides unique targets for the
rium across the membrane).development of selective KATPCOs giving focused therapeutic
Thus, opening of K1 channels is a fundamental physio-approaches to clinical conditions for example cardiac ischemia,
logical means for reversal or prevention of depolarizingurinary incontinance, neurodegeneration, obesity and autoim-
mune diseases. BKCa channels are found in a diverse array of activity of the membrane. The role of K1 channels in
tissues and due to voltage and Ca sensitivity may work as a cellular control and their opening by endogenous sub-
negative feedback process. A variety of small synthetic mole- stances (neurotransmitters, hormones and other media-cules (for example, NS004, fenamates) and natural product-
tors) is a recognized inhibitory mechanism. Syntheticderived compounds (DHS-I, maxikdiol) have been identified as
agents that decrease cell excitability, due to hyperpolar-selective BKCa channel openers which should have a profound
impact in controlling diseases. The discovery of numerous vari- ization of cell membranes following K1 channel opening,
ants of the a subunit (ion conductance pore) and b subunit will offer a major novel therapeutic approach. In addi-
(contributes biophysical and pharmacological properties) com- tion, K1 channels are a diverse and ubiquitous group ofplex of the BKCa channel gives potential to target specific tissues
ion channels exhibiting a broad range of physiologicalwith selective openers. Little is known, however, about the
roles in cell control processes. Therefore, drugs withsite(s) of interaction of openers of these channels. The discov-
ery of K1 channel subtype-specific openers and their evaluation potassium channel opening properties will have a broad
in different diseases will determine the degree to which these clinical potential.
channels (KATP, BKCa), or their isoforms, represent realistic Synthetic potassium channel openers (KCOs) have been
identified for two primary classes of K1 channel, adeno-
sine 59-triphosphate (ATP)-sensitive K1 channels (KATP)Key words: transmembrane ions, extracellular membrane, equilibrium
potential, hyperpolarization, synthetic KCOs. and high conductance Ca21-activated K1 channels
(BKCa) [1, 2]. KATP channels, which belong to the inwardÓ 2000 by the International Society of Nephrology
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rectifier K1 channel superfamily, are regulated by the ing pharmacology (Fig. 1) [1, 12]. Although this is a group
of heterogeneous organic molecules, attempts have beenintracellular ATP concentration [3, 4]; an increase in
made to propose a common pharmacophoric feature [hy-[ATP]i results in closure of the KATP channel. BKCa chan-
drophobic group(s), an electron-deficient aromatic ringnels, which belong to the voltage-dependent K1 channel
and hydrogen bonding site(s)] [13, 14]. Such featuressuperfamily, are activated by increases in [Ca21]i and
might support a single and common site of action forare sensitive to depolarization [2, 5]. The BKCa channel
KATPCOs (the subscript to the K indicates the postulatedprovides a link between the cell activity and the mem-
channel involved); however, this hypothesis is not consis-brane conductance of K1 ions and as such may work as
tent with the heterogeneity of the pharmacology re-a negative feedback process, especially in highly active
ported (Fig. 2) [1]. For example, diazoxide opens KATPcells.
channels in pancreatic b cells and vascular smooth mus-The first indication of K1 channel opening properties
cle cells, but demonstrates “antagonist” activity in car-in a synthetic compound was demonstrated, in pig coro-
diac cells and is “inactive” in skeletal muscle cells. In
nary and mesenteric arteries, with the anti-anginal agent
contrast, the KATPCOs pinacidil, cromakalim and nico-nicorandil [6, 7]. This nicotinamide hyperpolarized the randil open KATP channels in vascular smooth muscle andmembrane potential of the smooth muscle cells toward cardiac cells (at higher concentrations), but have no (or
the EK, this effect was associated with increased K1 con- very little) effect in pancreatic b cells. Further, the sensi-
ductance. These actions presented a physiological re- tivity of the effects of KATPCOs to inhibition by the sulfo-
sponse of vasorelaxation [6]. Nicorandil, however, also nylureas is tissue dependent [1, 12]. Therefore, the phar-
possesses additional properties (for example, NO dona- macology of the KATP channels, as characterized by the
tion) to that of direct K1 channel opening that account KATPCOs and sulfonylureas, is tissue dependent and in-
for the physiological effects observed [6, 8]. These find- dicative of multiple subtypes.
ings demonstrated that K1 channels are a realistic target Development of second generation KATPCOs (primar-
for synthetic molecules to evoke cell stabilization. The ily benzopyran, cyanoguanidine and nicotinamide struc-
benzopyran, cromakalim, demonstrated a pharmacologi- tures) through rational design and the identification of
cal profile similar to that of nicorandil, whereby smooth new chemical families exhibiting KATPCO properties have
provided agents with greater tissue selectivity. Combiningmuscle relaxation was the result of K1 channel opening
the structural features of cromakalim and pinacidil led toand hyperpolarization of the membrane potential to-
the synthesis of compounds (for example, BMS-180448,wards the EK [9]. In contrast to nicorandil, K1 channel
BMS-182264) that selectively exhibited the vascular oropening properties were reported as the principal mecha-
cardiac properties of these agents (Fig. 3) [13]. Thesenism of action responsible for the physiological effects
studies not only allow the identification of tissue selectiv-of cromakalim [10].
ity by uncoupling the smooth muscle relaxation fromConsistent with the involvement of K1 channels, the
cardiac actions within the pharmacophore of KATPCOs,effects of cromakalim and nicorandil were attenuated
but also indicate that modifications of existing structuresby nonselective inhibitors for example procaine, 4-
can provide the selective profiles sought. Selectivity be-aminopyridine and tetraethyl ammonium ions (TEA1)
tween different smooth muscle types (for example, respi-[11]. The effects of these KCOs were also sensitive to
ratory or urinary bladder vs. vascular) have also beeninhibition by the sulfonylureas (for example, glibenclam-
reported [15]. For example, simple modifications in the
ide, tolbutamide), selective inhibitors of KATP channels 6-position of the benzopyran structure of cromakalim
[1, 12]. Electrophysiological studies supported the open- has led to apparent respiratory smooth muscle selective
ing of KATP channels as the mechanism of action, where agents (for example, rimakalim, BRL55834). New chem-
the increased KATP currents due to cromakalim and nicor- ical groups of KATPCOs (anilide tertiary carbinols (for
andil were attenuated following an increase in [ATP]i example, ZD6169) and dihydropyridines (for example,
[1, 12]. These results were an impetus to identify other ZM244085) that display in vivo urinary bladder relaxant
molecules demonstrating selective K1 channel opening activity, but are devoid of potent hypotensive effects,
properties. In addition, due to the diversity and ubiqui- have been described. Recently, discrimination between
tous nature of K1 channels, the identity of the target different vascular beds also has been observed whereby
subtype(s) for KCOs was sought. selective relaxation of coronary arteries was exhibited
The term “potassium channel openers” (KCO) was by second generation KATPCOs (for example JTV506)
introduced to describe agents like cromakalim and nicor- [16]. In addition to the opening of K1 channels (for
andil with such properties. A diverse range of synthetic example, KATP channels) being a realistic mechanism by
molecules, identified empirically, have subsequently which synthetic molecules can evoke cellular stabiliza-
tion, a heterogeneous pharmacology and tissue selectivedemonstrated sulfonylurea-sensitive K1 channel open-
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Fig. 1. Chemical structures of potassium ATP-sensitive K1 channel openers (KATPCOs).
Fig. 2. Heterogeneous pharmacology of
KATPCOs. Activation of KATP channels by
those agents is indicated by check marks, and
no or very little effect is indicated by x.
KATPCOs support the potential for focused therapies in to the KATPCO, diazoxide, and the sulfonylureas repre-
sentative of pancreatic b cell KATP channels. The pharma-a broad range of clinical settings.
The recent cloning and expression of the sulfonylurea cology of the SUR2A/Kir6.2 complex (activated by pi-
nacidil, cromakalim and nicorandil, but not diazoxide)receptor has provided significant insight into an under-
standing of the observed heterogeneity of the pharmacol- is compatible with KATP channels found in cardiac cells.
All four KATPCOs activated the SUR2B/Kir6.2 complexogy of KATPCOs [17]. Evidence suggests that KATP chan-
nels are composed of two subunits, a regulatory protein with pharmacology potency profiles as observed in the
native KATP channels of vascular smooth muscle. SUR2Bcontaining the sulfonylurea binding site or receptor
(SUR) and an inward rectifying K1 channel (Kir6.2) differs from SUR2A in the 42 amino acid residues lo-
cated at the carboxyl terminus, suggesting that this mayserving as the pore forming subunit, each obtaining a
tetrameric formation. Expression of both subunits (SUR/ be a functional domain important for activation by di-
azoxide and the potency increase (relative to SUR2A)Kir6.2) is required for a functional KATP channel and the
SUR component plays an essential role in conferring of the other KATPCOs (pinacidil, cromakalim and nicora-
ndil; Fig. 4). The 42 amino acid residues in the carboxylpharmacological properties of the KATPCOs to the chan-
nel [17]. A family of SUR isoforms (SUR1, SUR2A, terminus of SUR1 and SUR2B are common, supporting
the importance of this region for the activity of diazoxide.SUR2B) have been identified that on expression with
Kir6.2 exhibit a heterogeneous pharmacology (Fig. 4) Further, the site responsible for the activity (as opposed
to potency modulation) of the other KATPCOs appears[18]. The SUR1/Kir6.2 complex demonstrates sensitivity
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Fig. 3. Tissue selective KATPCOs. Compounds combining the structural features of cromakalim and pinacidil have allowed the uncoupling of
vascular smooth muscle relaxation from the cardiac actions of these KATPCOs.
Fig. 4. KATPCO pharmacology of the sulpho-
nylurea receptor (SUR) isoforms. Activation
of the KATP channel formed from expressed
Kir6.2 and the SUR isoform shown is indi-
cated by D, P, C and N for diazoxide, pinacidil,
cromakalim and nicorandil, respectively. Per-
centage values respresent the identity levels
of the different SUR isoforms.
to be distinct from that for diazoxide, probably located though a further splice variant of SUR2 (SUR2C) has
been cloned that may be localized to vascular structureswhere SUR2A and SUR2B lack identity with SUR1.
Thus, the heterogeneity of the pharmacology of the [19], a pharmacological profile is awaited. However,
SUR isoforms also appear capable of complexing withKATPCOs observed in functional physiologic and electro-
physiologic studies is compatible with the structural di- more than one subtype of Kir (for example, Kir 6.1,
ROM K1) [20]. As the Kir subunit is responsible for theversity of the cloned KATP channels (SUR/Kir6.2 com-
plexes). It is pertinent to mention that the pharmacology conduction properties of the channel, such diversity in
structure may explain the heterogeneity observed in cer-of the KATPCOs observed in, for example, vascular
smooth muscle tissues [1] cannot be fully accounted by tain experiments.
Preclinical (and limited clinical) studies have pre-the SUR isoforms SUR1, SUR2A and SUR2B. Al-
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Fig. 5. Therapeutic targets for KATPCOs. Pre-
clinical and limited clinical studies have dem-
onstrated effects for one or more of the
KATPCOs in a broad spectrum of tissues. SUR
isoforms are indicated where they represent
the target for the KATPCOs.
sented effects for one or more of the KATPCOs in a broad smooth muscle cells, skeletal muscle cells, neuronal cells
and secretary epithelial cells) [1, 23]. Further, BKCa chan-spectrum of tissues, including neuronal, cardiac muscle,
smooth muscle (vascular, reproductive, gastrointestinal, nels are preferentially transported to, and inserted in,
the presynaptic bouton and therefore are very importanturinary bladder, respiratory), skeletal muscle and endo-
crine cells (Fig. 5) [1]. As a consequence of the ubiquitous in the control of neurotransmitter and hormone release.
The physiological role and distribution of BKCa chan-nature of the targets for KATPCOs a lack of selectivity
(tissue) has been observed. Drugs already marketed nels suggests that agents that open these channels could
have a profound impact on controlling disease (espe-which open K1 channels were discovered empirically
and most have serious safety and efficacy problems [1, cially associated with BKCa channels). Such drugs will
not only have therapeutic potential, but will be of assis-12]. The rational design of molecules demonstrating
KATPCO properties should allow interpretation of the tance in understanding the function, structure and role
of BKCa channels. The BKCa current may, however, varyheterogeneous pharmacology observed, provide tools to
identify target channel subtypes and through increased from cell to cell depending on membrane potential, inter-
nal Ca21 concentration and phosphorylation of the chan-selectivity reduce potential side effects. Current progress
regarding the design of KATP channel openers is providing nel, so functional effects of increasing the current are
difficult to predict [2]. The expected effects of BKCaCOsimportant leads that will selectively activate discretely
located KATP channel isoforms offering a realistic poten- should generally be small on the resting membrane po-
tential, larger on the action potential, and most pro-tial of focussed therapies for certain pathophysiological
conditions. Development of selective KATPCOs can be nounced on very active cells.
The discovery of the first small molecules and naturalconsidered for clinical conditions as diverse as cardiac
ischemia, urinary incontinance, asthma, dysmenorrhea, product derived modulators have made BKCa channels
practical drug targets (Figs. 6 and 7). The benzimidazo-pain, neurodegeneration, obesity and autoimmune dis-
eases. lones NS004 and NS1619 initiated the prospect of small
molecule openers of BKCa channels [1, 2, 24]. In a diverseThe diversity of K1 channel subtypes and their impor-
tance in physiological (cellular) control is an impetus to array of cell types using a variety of electrophysiological
techniques, extracellular or intracellular applied NS004identify compounds that open other K1 channel sub-
types. The large conductance calcium-activated K1 chan- and NS1619 activated BKCa currents, effects that were
potentiated by increasing [Ca21]i [2, 25]. The gating stim-nels (BKCa channels) have emerged as a target for which
specific synthetic openers have been identified. Calcium- ulated by BKCaCO benzimidazolones was similar to that
mediated by an increased internal Ca21 concentration,activated K1 channels are broadly classified into three
primary groups on the basis of their conductance profiles, indicating that the compounds did not induce new kinetic
states [25]. The involvement of BKCa channels was sup-voltage dependence and pharmacology [21]. BKCa chan-
nels may work as a negative feedback process due to ported by attenuation of the effects to these agents by
the selective inhibitors charybdotoxin and iberiotoxin.voltage and Ca21 sensitivity to regulate the degree of
membrane depolarization and provide a link between A diverse range of small molecules (such as fenamates,
benzopyrans, dihydropyridines, flavoids) that open BKCathe cell activity and the membrane conductance, espe-
cially in highly active cells [1, 22]. These channels are channels have subsequently been empirically identified
(Fig. 6) [2, 5]. The limitation of the small moleculepresent in a number of organ systems (for example, all
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Fig. 6. Chemical structures of small molecule high conductance Ca21-activated K1 channel openers (BKCaCOs).
BKCaCOs identified thus far is the lack of selectivity sive classification has yet been defined. The discovery of
for this channel over other mechanisms. In addition to numerous variants of the a- and b-subunit complexes of
the small molecules, several natural products (for exam- the BKCa channel gives researchers the potential to target
ple, DHS-I, maxiKdiol, L-735,334) have been identified specific channels and tissues. Because of the widespread
as BKCaCOs (Fig. 7) [2, 5]. These observations demon- tissue distribution and dependence on both voltage and
strate a realistic potential of compounds to open K1 calcium for activation, BKCa channels are seen as a poten-
channel subtypes different from that of KATP channels. tial therapeutic target for numerous disorders. Few stud-
The molecular structure of the BKCa channel is com- ies have investigated the effects of BKCaCOs in tissue
posed of two moieties, a pore forming a-subunit and a preparations or in whole animals, due to lack of selectiv-
regulatory protein b-subunit [26, 27]. The a-subunit, a ity of these agents. Nevertheless, it can be anticipated
member of the Slo gene family, has six putative trans- that selective BKCaCOs will offer the opportunity to in-
membrane segments, a pore region and a long internal tervene in the consequences of, at least, neuronal and
carboxyl terminus (expressing Ca21 sensitivity and possi- muscular hyperexcitability.
bly forming a further 4 transmembrane segments). The In conclusion, synthetic molecules that open K1 chan-
b-subunit consists of two putative transmembrane seg- nels offer a novel therapeutic approach of stabilizing and
ments and a large extracellular loop. The small molecule controlling cellular function. Therefore, the discovery
BKCaCOs (for example, benzimidazolones, fenamates) of new K1 channel subtype-specific openers and their
and the natural product, maxiKdiol, activated a BKCa evaluation in different diseases will determine the degree
current when the cloned a-subunit was expressed alone to which these classes of channels (KATP, BKCa) represent
[2, 5]. In contrast, DHS-I only expressed BKCa channel a realistic therapeutic target. New scientific methods,
opening properties when the a-subunit was coexpressed utilizing molecular insight, are implicating K1 channel
with the b-subunit [28]. Such pharmacological tools will dysfunction in certain disease states and identifying new
help define the site(s) on this protein complex where drug targets for more successful K1 channel opening
agents can bind to activate the channel, and through drugs.
rational design selective BKCaCOs offering a new direc-
Reprint requests to Dr. Kim Lawson, Biomedical Research Centre,tion in therapeutic approaches will be available. Native
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BKCa channels have been shown to exist in a number of United Kingdom.
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Fig. 7. Chemical structures of natural product BKCa COs.
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